宏源药业发布前三季度业绩，归母净亏损110.02万元

Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) reported a slight decline in revenue for the first three quarters of 2025, indicating potential challenges in maintaining growth [1] Financial Performance - The company's operating revenue for the first three quarters was 1.317 billion yuan, representing a year-on-year decrease of 0.39% [1] - The net loss attributable to shareholders of the listed company was 1.1002 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 24.4001 million yuan [1] - The basic loss per share was 0.0028 yuan [1]